文献速递临床生化临床免疫

将载脂蛋白B转化为等效LDL-C以辅助临床决策的转化工具

A Translational Tool to Facilitate Use of Apolipoprotein B for Clinical Decision-Making.
PubMed 文献 · Clin Chem · 2023-01-01

研究发现LDL-C与apoB不一致普遍存在,低LDL-C者40%apoB更高,高LDL-C者49%apoB更低,提示apoB可用于ASCVD风险评估。

要点

  • apoB可通过公式转换为等效LDL-C百分位单位,便于使用LDL-C目标指导治疗。
  • LDL-C与apoB不一致常见,低LDL-C者40%apoB更高,高LDL-C者49%apoB更低。
  • 仅25%-40%患者apoB与LDL-C一致,提示应关注apoB以改善风险分层。

核心结论

  • apoB与LDL-C不一致普遍存在,将apoB转换为等效LDL-C单位有助于推动apoB用于ASCVD风险管理。

研究设计与样本

  • sequentially collected population-based samples underwent standard lipid panel and apoB immunoassay; those with triglycerides >1000 mg/dl excluded; final cohort 15 153 individuals.

主要发现

  • Linear regression of calculated LDL-C against percentile-equivalent apoB yielded equation: LDL-C equivalents = 1.38(apoB) - 29 (R² = 0.999).
  • Among individuals with very low LDL-C (55-70 mg/dL), 40% had discordantly higher apoB.
  • Of those with very high LDL-C (175-190 mg/dL), 49% had discordantly lower apoB.
  • Across the range, a minority of patients (25%-40%) had concordant levels of apoB.
  • Similar results were found in discordance analysis between apoB and non-HDL-C.

关键数值与推荐

  • Conversion formula: LDL-C equivalents = 1.38(apoB) - 29 (R² = 0.999).
  • Discordance prevalence: 40% higher apoB in very low LDL-C; 49% lower apoB in very high LDL-C; concordance 25%-40%.

临床怎么用

  • 可利用转换公式将apoB值转为等效LDL-C单位,结合LDL-C目标进行降脂治疗决策。
  • 应关注LDL-C与apoB不一致,尤其低LDL-C但apoB高者提示更高ASCVD风险。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite recent large-scale discordance studies showing definitively that atherosclerotic cardiovascular disease (ASCVD) risk correlates better with apolipoprotein B (apoB) than with low-density lipoprotein cholesterol (LDL-C), the latter remains the recommended metric for guiding lipid-lowering treatment decisions in the United States. A major barrier to change, in this regard, is the lack of guideline-recommended apoB treatment targets. We developed a simple method to "translate" apoB values into population-equivalent LDL-C units, allowing apoB-based treatment decisions to be made using LDL-C targets. METHODS: Sequentially collected, population-based samples underwent standard lipid panel analysis and apoB testing by immunoassay. Those with triglycerides greater than 1000 mg/dl were excluded, leaving a study cohort of 15 153 individuals. RESULTS: Linear regression of calculated LDL-C values against percentile-equivalent apoB values yielded an equation to convert apoB into percentile-equivalent LDL-C units: [LDL-C equivalents = 1.38(apoB) - 29] (R2 = 0.999). The extent of discordance between LDL-C and apoB was examined in subgroups with similar LDL-C, ranging from very low (55-70 mg/dL) to very high (175-190 mg/dL). Among individuals with very low LDL-C, 40% had discordantly higher apoB, indicating higher ASCVD risk. Of those with very high LDL-C, 49% had discordantly lower apoB. Across the range, a minority of patients (25%-40%) had concordant levels of apoB, confirming that discordance between these biomarkers is highly prevalent. Similar results were found in discordance analysis between apoB and non-high-density lipoprotein cholesterol (HDL-C). CONCLUSIONS: Providing visibility to discrepancies among LDL-C, non-HDL-C, and apoB should help to facilitate more rapid and widespread adoption of apoB for managing ASCVD risk.

来源:Clin Chem,查看原文。版权归原作者所有。

引用

  1. Cole J, Otvos JD, Remaley AT, et al. A Translational Tool to Facilitate Use of Apolipoprotein B for Clinical Decision-Making. Clin Chem. 2023. PMID: 36366949. doi:10.1093/clinchem/hvac161

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。